Patiromer for hyperkalaemia in heart failure

Area of Science:

• Cardiology
• Pharmacology
• Heart Failure Management

Background:

• Hyperkalemia is a common complication in patients with heart failure with reduced ejection fraction (HFrEF).
• Hyperkalemia often necessitates the discontinuation or reduction of renin-angiotensin-aldosterone system inhibitors (RAASis), crucial for HFrEF management.
• Patiromer is a potassium-binding polymer indicated for treating hyperkalemia.

Purpose of the Study:

• To evaluate the efficacy and safety of patiromer for managing hyperkalemia in patients with HFrEF.
• To assess the impact of patiromer on RAASi therapy in this patient population.

Main Methods:

• The DIAMOND trial was a randomized, double-blind, placebo-controlled study.
• Patients with HFrEF and hyperkalemia were randomized to receive patiromer or placebo.
• The primary endpoint was the change in serum potassium levels over time.

Main Results:

• Patiromer significantly reduced serum potassium levels compared to placebo.
• A greater proportion of patients in the patiromer group achieved and maintained normal potassium levels.
• Patiromer was generally well-tolerated, with a favorable safety profile.

Conclusions:

• Patiromer is an effective treatment for hyperkalemia in patients with HFrEF.
• Patiromer facilitates the use and titration of RAASi therapy in HFrEF patients.
• The DIAMOND trial supports the use of patiromer in optimizing heart failure management.